Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1999 2
2001 1
2006 2
2008 1
2009 1
2010 3
2011 6
2012 7
2013 8
2014 13
2015 24
2016 49
2017 44
2018 62
2019 75
2020 87
2021 113
2022 117
2023 127
2024 44

Text availability

Article attribute

Article type

Publication date

Search Results

686 results

Results by year

Filters applied: . Clear all
Page 1
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
Alam H, Tang M, Maitituoheti M, Dhar SS, Kumar M, Han CY, Ambati CR, Amin SB, Gu B, Chen TY, Lin YH, Chen J, Muller FL, Putluri N, Flores ER, DeMayo FJ, Baseler L, Rai K, Lee MG. Alam H, et al. Cancer Cell. 2020 Apr 13;37(4):599-617.e7. doi: 10.1016/j.ccell.2020.03.005. Epub 2020 Apr 2. Cancer Cell. 2020. PMID: 32243837 Free PMC article.
Histone methyltransferase KMT2D (a COMPASS-like enzyme, also called MLL4) is among the most highly inactivated epigenetic modifiers in lung cancer. ...Pharmacological inhibition of glycolysis preferentially impedes tumorigenicity of human lung cancer cells be …
Histone methyltransferase KMT2D (a COMPASS-like enzyme, also called MLL4) is among the most highly inactivated epigenetic modifiers i …
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.
Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA, Baselga J. Toska E, et al. Science. 2017 Mar 24;355(6331):1324-1330. doi: 10.1126/science.aah6893. Science. 2017. PMID: 28336670 Free PMC article.
We found that PI3Kalpha inhibition mediates an open chromatin state at the ER target loci in breast cancer models and clinical samples. KMT2D, a histone H3 lysine 4 methyltransferase, is required for FOXA1, PBX1, and ER recruitment and activation. AKT binds and phos …
We found that PI3Kalpha inhibition mediates an open chromatin state at the ER target loci in breast cancer models and clinical sample …
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition.
Pan Y, Han H, Hu H, Wang H, Song Y, Hao Y, Tong X, Patel AS, Misirlioglu S, Tang S, Huang HY, Geng K, Chen T, Karatza A, Sherman F, Labbe KE, Yang F, Chafitz A, Peng C, Guo C, Moreira AL, Velcheti V, Lau SCM, Sui P, Chen H, Diehl JA, Rustgi AK, Bass AJ, Poirier JT, Zhang X, Ji H, Zhang H, Wong KK. Pan Y, et al. Cancer Cell. 2023 Jan 9;41(1):88-105.e8. doi: 10.1016/j.ccell.2022.11.015. Epub 2022 Dec 15. Cancer Cell. 2023. PMID: 36525973 Free PMC article.
Lung squamous cell carcinoma (LUSC) represents a major subtype of lung cancer with limited treatment options. KMT2D is one of the most frequently mutated genes in LUSC (>20%), and yet its role in LUSC oncogenesis remains unknown. Here, we identify KMT2D as …
Lung squamous cell carcinoma (LUSC) represents a major subtype of lung cancer with limited treatment options. KMT2D is one of …
KMT2C and KMT2D aberrations in breast cancer.
Tinsley E, Bredin P, Toomey S, Hennessy BT, Furney SJ. Tinsley E, et al. Trends Cancer. 2024 Mar 6:S2405-8033(24)00029-3. doi: 10.1016/j.trecan.2024.02.003. Online ahead of print. Trends Cancer. 2024. PMID: 38453563 Review.
KMT2C and KMT2D are histone lysine methyltransferases responsible for the monomethylation of histone 3 lysine 4 (H3K4) residues at gene enhancer sites. ...Recent studies using cell lines and mouse models to replicate KMT2C/D loss show that these genes contribute to oestrog …
KMT2C and KMT2D are histone lysine methyltransferases responsible for the monomethylation of histone 3 lysine 4 (H3K4) residues at ge …
Histone H3 lysine 4 methyltransferase KMT2D.
Froimchuk E, Jang Y, Ge K. Froimchuk E, et al. Gene. 2017 Sep 5;627:337-342. doi: 10.1016/j.gene.2017.06.056. Epub 2017 Jun 29. Gene. 2017. PMID: 28669924 Free PMC article. Review.
The C-terminal SET domain is responsible for its H3K4 methyltransferase activity and is necessary for maintaining KMT2D protein stability in cells. KMT2D associates with WRAD (WDR5, RbBP5, ASH2L, and DPY30), NCOA6, PTIP, PA1, and H3K27 demethylase UTX in one protein …
The C-terminal SET domain is responsible for its H3K4 methyltransferase activity and is necessary for maintaining KMT2D protein stabi …
CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade.
Wang G, Chow RD, Zhu L, Bai Z, Ye L, Zhang F, Renauer PA, Dong MB, Dai X, Zhang X, Du Y, Cheng Y, Niu L, Chu Z, Kim K, Liao C, Clark P, Errami Y, Chen S. Wang G, et al. Cancer Discov. 2020 Dec;10(12):1912-1933. doi: 10.1158/2159-8290.CD-19-1448. Epub 2020 Sep 4. Cancer Discov. 2020. PMID: 32887696 Free PMC article.
Here, we performed pooled mutagenic screening with CRISPR-mediated genetically engineered mouse models (CRISPR-GEMM) in ICB settings, and identified KMT2D as a major modulator of ICB response across multiple cancer types. KMT2D encodes a histone H3K4 methyltr …
Here, we performed pooled mutagenic screening with CRISPR-mediated genetically engineered mouse models (CRISPR-GEMM) in ICB settings, and id …
KMT2D promotes proliferation of gastric cancer cells: evidence from ctDNA sequencing.
Li Q, Wu R, Wu F, Chen Q. Li Q, et al. J Clin Lab Anal. 2021 Apr;35(4):e23721. doi: 10.1002/jcla.23721. Epub 2021 Apr 1. J Clin Lab Anal. 2021. PMID: 33793001 Free PMC article.
Immunohistochemical examination was conducted to assess the expression of KMT2D in gastric cancer tissues. KMT2D knockdown was performed to establish the stably transfected gastric cancer cells. ...The high-frequency mutant gene KMT2D was identi …
Immunohistochemical examination was conducted to assess the expression of KMT2D in gastric cancer tissues. KMT2D knockd …
Lysine Demethylase KDM6A in Differentiation, Development, and Cancer.
Tran N, Broun A, Ge K. Tran N, et al. Mol Cell Biol. 2020 Sep 28;40(20):e00341-20. doi: 10.1128/MCB.00341-20. Print 2020 Sep 28. Mol Cell Biol. 2020. PMID: 32817139 Free PMC article. Review.
KDM6A physically associates with histone H3 lysine 4 monomethyltransferases MLL3 (KMT2C) and MLL4 (KMT2D). Since its identification as an H3K27 demethylase in 2007, studies have reported KDM6A's critical roles in cell differentiation, development, and cancer. ...Mut …
KDM6A physically associates with histone H3 lysine 4 monomethyltransferases MLL3 (KMT2C) and MLL4 (KMT2D). Since its identification a …
KMT2D links TGF-beta signaling to noncanonical activin pathway and regulates pancreatic cancer cell plasticity.
Lu S, Kim HS, Cao Y, Bedi K, Zhao L, Narayanan IV, Magnuson B, Gu Y, Yang J, Yi Z, Babaniamansour S, Shameon S, Xu C, Paulsen MT, Qiu P, Jeyarajan S, Ljungman M, Thomas D, Dou Y, Crawford H, di Magliano MP, Ge K, Yang B, Shi J. Lu S, et al. Int J Cancer. 2023 Aug 1;153(3):552-570. doi: 10.1002/ijc.34528. Epub 2023 May 4. Int J Cancer. 2023. PMID: 37140208
We observed a decreased KMT2D expression in human primary and metastatic pancreatic cancer. Furthermore, inhibition or knockdown of activin A reversed the protumoral role of KMT2D loss. These findings support a tumor-suppressive role of KMT2D in pancre …
We observed a decreased KMT2D expression in human primary and metastatic pancreatic cancer. Furthermore, inhibition or knockdo …
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S, Yim S, Park H. Chang S, et al. Exp Mol Med. 2019 Jun 20;51(6):1-17. doi: 10.1038/s12276-019-0230-6. Exp Mol Med. 2019. PMID: 31221981 Free PMC article. Review.
Recent studies on mutations in cancer genomes have distinguished driver mutations from passenger mutations, which occur as byproducts of cancer development. The cancer genome atlas (TCGA) project identified 299 genes and 24 pathways/biological processes that …
Recent studies on mutations in cancer genomes have distinguished driver mutations from passenger mutations, which occur as byproducts …
686 results